Get the Stockscreener App
3.65
1.08%
-0.04
Sutro Biopharma Inc stock is traded at $3.65, with a volume of 217.58K.
It is down -1.08% in the last 24 hours and up +1.11% over the past month.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
See More
Previous Close:
$3.69
Open:
$3.71
24h Volume:
217.58K
Relative Volume:
0.37
Market Cap:
$302.45M
Revenue:
$153.73M
Net Income/Loss:
$-106.79M
P/E Ratio:
-1.4777
EPS:
-2.47
Net Cash Flow:
$-115.93M
1W Performance:
+2.82%
1M Performance:
+1.11%
6M Performance:
-4.70%
1Y Performance:
+28.07%
1-Day Range:
$3.595
$3.815
1-Week Range:
$3.22
$3.815
52-Week Range:
$2.005
$6.13
Sutro Biopharma Inc Stock (STRO) Company Profile
Name
Sutro Biopharma Inc
Sector
Industry
Phone
650-392-8412
Address
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jun-18-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Jul-16-20 | Initiated | Wells Fargo | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Oct-07-19 | Initiated | BTIG Research | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Apr-29-19 | Initiated | H.C. Wainwright | Buy |
| Oct-22-18 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
| Oct-22-18 | Initiated | Wedbush | Outperform |
View All
Sutro Biopharma Inc Stock (STRO) Latest News
Vanguard Group Inc's Strategic Acquisition in Sutro Biopharma Inc - GuruFocus.com
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference - The Manila Times
Sutro Biopharma begins trial of acute myeloid leukaemia treatment in children - Clinical Trials Arena
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of “Buy” from Brokerages - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $12.13 Average PT from Brokerages - MarketBeat
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML - The Manila Times
Sutro Biopharma's SWOT analysis: stock poised for growth amid clinical progress - Investing.com
The Manufacturers Life Insurance Company Buys 7,082 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma (NASDAQ:STRO) shareholders have endured a 80% loss from investing in the stock three years ago - Yahoo Finance
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Cubist Systematic Strategies LLC - MarketBeat
Sutro Biopharma: Post ESMO Selloff, Does Their Strategy In FRα Remain Viable? - Seeking Alpha
Sutro Biopharma Inc Inc. (STRO) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle
Algert Global LLC Reduces Stake in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
AQR Capital Management LLC Boosts Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
AQR Capital Management LLC Buys 247,694 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Sutro Biopharma (NASDAQ:STRO) - Defense World
Sutro Biopharma (NASDAQ:STRO) & Palisade Bio (NASDAQ:PALI) Head-To-Head Contrast - Defense World
Piper Sandler sustains Overweight rating on Sutro Biopharma shares By Investing.com - Investing.com Canada
Sutro Biopharma retains stock target with Buy rating on key advancements - Investing.com Canada
Peeling Back The Layers: Exploring Sutro Biopharma Through Analyst Insights - Benzinga
Sutro Biopharma (NASDAQ:STRO) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive - Simply Wall St
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Dimensional Fund Advisors LP - MarketBeat
After-Market Gains For Sutro Biopharma (STRO) Following An Investor Webcast - Stocks Telegraph
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum - GlobeNewswire
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $12.13 Average Price Target from Analysts - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Bought by ProShare Advisors LLC - Defense World
Cubist Systematic Strategies LLC Trims Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Millennium Management LLC Has $12.78 Million Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
It would be worthwhile to take a closer look at Sutro Biopharma Inc (STRO) - US Post News
Financial Metrics Unveiled: Sutro Biopharma Inc (STRO)’s Key Ratios in the Spotlight - The Dwinnex
American Century Companies Inc. Trims Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Susquehanna Fundamental Investments LLC Grows Stake in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Renaissance Technologies LLC Buys 233,700 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
A better buy-in window may exist right now for Sutro Biopharma Inc (STRO) - SETE News
XTX Topco Ltd Has $95,000 Stock Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Point72 Asset Management L.P. Increases Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Investing in Sutro Biopharma Inc (STRO) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Sutro Biopharma's SWOT analysis: ADC developer's stock faces pivotal year By Investing.com - Investing.com Canada
Sutro Biopharma's SWOT analysis: ADC developer's stock faces pivotal year - Investing.com India
STRO (Sutro Biopharma) Enterprise Value : $-114.2 Mil (As of Sep. 28, 2024) - GuruFocus.com
Check out these key findings about Sutro Biopharma Inc (STRO) - SETE News
STRO’s 2023 Market Dance: Down -20.75% – Time to Invest? - The InvestChronicle
Sutro Biopharma Inc (STRO) presents a great opportunity, but the stock is slightly undervalued - US Post News
Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology - Seeking Alpha
Sutro Biopharma Inc’s Market Journey: Closing Weak at 3.77, Down -3.83 - The Dwinnex
Bank of New York Mellon Corp Increases Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - ForexTV.com
Institutional investors may overlook Sutro Biopharma, Inc.'s (NASDAQ:STRO) recent US$43m market cap drop as long-term gains remain positive - Simply Wall St
Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players - Benzinga
Ready to Jump After Recent Trade: Sutro Biopharma Inc (STRO) - SETE News
Sutro Biopharma Inc Stock (STRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sutro Biopharma Inc Stock (STRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chung Jane | PRESIDENT AND COO |
Aug 09 '24 |
Option Exercise |
0.00 |
18,750 |
0 |
60,951 |
| Srinivasan Venkatesh | CHIEF TECH OP OFFICER |
May 01 '24 |
Option Exercise |
0.00 |
2,500 |
0 |
32,622 |
| Srinivasan Venkatesh | CHIEF TECH OP OFFICER |
Apr 11 '24 |
Option Exercise |
0.00 |
21,250 |
0 |
37,704 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 05 '24 |
Option Exercise |
0.00 |
8,750 |
0 |
76,060 |
| NEWELL WILLIAM J | CEO |
Mar 05 '24 |
Option Exercise |
0.00 |
18,750 |
0 |
226,893 |
| ALBINI EDWARD C | CFO AND SECRETARY |
Mar 05 '24 |
Option Exercise |
0.00 |
8,750 |
0 |
109,843 |
| NEWELL WILLIAM J | CEO |
Mar 04 '24 |
Option Exercise |
0.00 |
31,125 |
0 |
219,248 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 04 '24 |
Option Exercise |
0.00 |
9,125 |
0 |
71,049 |
| Chung Jane | PRESIDENT AND COO |
Mar 04 '24 |
Option Exercise |
0.00 |
7,875 |
0 |
44,410 |
| ALBINI EDWARD C | CFO AND SECRETARY |
Mar 04 '24 |
Option Exercise |
0.00 |
9,125 |
0 |
104,565 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):